Lorlatinib is a molecule of the third-generation approved in 2018 by the FDA in the first-line setting for metastatic NSCLC patients and ALK rearrangement with progressive disease on crizotinib and other ALK inhibitors [114,115]. This evidence concerns the gene ALK and non-small cell lung carcinoma.